Reach Us +44-1904-929220


Value of the TruGraf Blood Test as a Biomarker for Monitoring Renal Transplant Recipients

Kidney transplantation is the optimal treatment for many patients with end-stage kidney disease. The short-term outcomes of kidney transplantation have improved in the past few decades as a result of development of newer immunosuppressive drugs, more effective anti-microbial prophylaxis, and improved surgical techniques; however, long-term outcomes remain suboptimal. Routine posttransplant monitoring consists of the measurement of serum creatinine (SCr) and immunosuppressive drug levels. However, both are insensitive and non-specific markers of graft damage.


First MR, Rose S, Schieve C, Lee D, Lewis P, Pierry D, David J, McNulty M, Clark D, Weiss G, Kurian S, Whisenant T, Friedewald JJ and Abecassis MM

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • Cosmos IF
  • Publons
  • Secret Search Engine Labs